Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience (NASDAQ:LEXX) announced a registered direct offering of 2,661,600 shares of common stock at $1.315 per share, with aggregate gross proceeds expected to be approximately $3.5 million before fees and expenses. The offering is priced at-the-market under Nasdaq rules and is expected to close on or about December 16, 2025, subject to customary conditions.
In a concurrent private placement the company will issue unregistered warrants to purchase up to 2,661,600 shares at an exercise price of $1.19 per share; the warrants are immediately exercisable and expire five years after effectiveness of the resale registration statement. H.C. Wainwright & Co. is sole placement agent. Net proceeds are intended for R&D, working capital and general corporate purposes.
Lexaria Bioscience (NASDAQ:LEXX, LEXXW) entered a definitive agreement for a registered direct offering of 2,666,667 common shares at $1.50 per share and a concurrent private placement of unregistered warrants to purchase up to 2,666,667 shares.
The warrants carry a $1.37 exercise price, are immediately exercisable and expire five years from the effectiveness of the resale registration statement. Aggregate gross proceeds are expected to be approximately $4.0 million before placement agent fees and expenses. The closing is expected on or about September 29, 2025, subject to customary conditions.
Proceeds are intended for working capital and general corporate purposes; the registered shares are offered under an effective Form S-3 shelf registration.
Lexaria (Nasdaq:LEXX) announced an extension to its Material Transfer Agreement with a pharmaceutical company through April 30, 2026 to allow PharmaCO time to receive and review the full dataset from Lexaria's Australian human study GLP-1-H24-4.
The extension keeps the temporary exclusive license active and preserves the parties' ability to continue strategic planning with PharmaCO's human clinical development team. Lexaria said initial pre-clinical pharmacokinetic animal studies under the MTA were completed earlier in 2025 and that final results from the Australian study are projected to be released before the end of Q4 2025.
Lexaria Bioscience (NASDAQ:LEXX) announced strategic updates including engagement of a global life‑science business development advisory firm, completion of an equity financing raising $4.0 million gross, and award of 4 new patents covering diabetes, epilepsy, antiviral delivery and infused food/beverage applications (grant dates Jul–Oct 2025).
The funding extends operations beyond 2025, supports expanded R&D into 2026, and enables increased outreach to pharmaceutical and biotech partners. Final results from a Phase 1b Australian GLP‑1 study are anticipated and further R&D budget decisions will be announced later.
Lexaria Bioscience (NASDAQ:LEXX) has successfully closed a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The offering consisted of 2,666,667 shares of common stock at $1.50 per share.
Additionally, the company issued unregistered warrants in a concurrent private placement to purchase up to 2,666,667 shares of common stock with an exercise price of $1.37 per share. These warrants are immediately exercisable and have a five-year expiration term.
H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes, with a focus on supporting their 2026 R&D and business development initiatives.
Lexaria Bioscience (NASDAQ:LEXX), a global drug delivery platform innovator, has announced a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,666,667 shares of common stock at $1.50 per share.
Additionally, in a concurrent private placement, Lexaria will issue unregistered warrants to purchase up to 2,666,667 shares with an exercise price of $1.37 per share. The warrants will be immediately exercisable and expire in five years. H.C. Wainwright & Co. serves as the exclusive placement agent, with the offering expected to close around September 29, 2025.
Lexaria Bioscience (Nasdaq:LEXX) has announced positive results from its fluorescently tagged semaglutide (FTS) rodent biodistribution study, demonstrating that its DehydraTECH technology enhances brain delivery of the GLP-1 drug semaglutide.
The study revealed that DehydraTECH-FTS showed higher brain biodistribution compared to Rybelsus® equivalent composition, with the 5mg DehydraTECH-FTS achieving higher brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent. The enhanced brain delivery could potentially improve both safety and efficacy of GLP-1 drugs, particularly in areas related to appetite suppression and nausea reduction.
These findings suggest that Lexaria's technology may enable unique delivery enhancements in brain tissue, potentially supporting improved pharmacodynamic performance of GLP-1 drugs.
Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference from September 8-10th, 2025.
CEO Richard Christopher will deliver a company presentation, which will be available for remote viewing starting September 5th at 7:00 AM EST. The management team will also be available for one-on-one meetings with investors throughout the conference.
Lexaria Bioscience (NASDAQ:LEXX) has achieved the Last Patient Last Visit (LPLV) milestone in its Phase 1b GLP-1 study in Australia. The study, designated as GLP-1-H24-4, is currently in the laboratory analysis phase where thousands of samples are being processed and analyzed.
The company previously reported positive 8-week interim results showing encouraging safety and tolerability data compared to the Rybelsus® control arm, particularly noting reduced gastrointestinal adverse events. The final report is expected in late 2025.
Lexaria Bioscience (NASDAQ:LEXX) provides an update on the expanding GLP-1 and obesity drug market, highlighting its DehydraTECH technology's potential role. The market is expected to exceed $150 billion by 2030, with 39 new GLP-1 drugs in development from 34 companies.
The company's DehydraTECH platform has demonstrated significant reductions in gastrointestinal adverse events across major GLP-1 drugs, showing improvements ranging from 31% to 100% in various studies. The update also details recent major industry deals, including Novo Nordisk's $2.2 billion collaboration with Septerna, Roche's $5.3 billion rights acquisition from Zealand Pharma, and Regeneron's $1.93 billion licensing deal with Hansoh Pharmaceutical.